Cleerly, a leader in cardiovascular AI imaging, will present groundbreaking research on gender-specific cardiovascular risk assessment at the upcoming American College of Cardiology Annual Scientific Session + Expo (ACC.25) in Chicago from March 29-31, 2025.
The company will unveil late-breaking clinical trial results demonstrating how their Artificial Intelligence-based Quantitative Computed Tomography (AI-QCT) technology can identify future major adverse cardiovascular events (MACE) in women with greater precision than traditional methods.
Dr. Gudrun Feuchtner will present the findings from the CONFIRM2 registry study on March 31st at 9:00 AM during the "Clinical and Investigative Horizons" session. The presentation, titled "Artificial Intelligence-based Quantitative Computed Tomography (AI-QCT) Coronary Plaque Features Predict Risk More Pronounced in Females: The International Multicentric Registry CONFIRM2," addresses a significant gap in cardiovascular care.
Addressing Gender Disparities in Cardiac Care
Coronary artery disease (CAD) remains consistently underdiagnosed and undertreated in women, contributing to preventable morbidity and mortality. The CONFIRM2 registry represents a significant advancement in this area, with approximately 50% female participation among its 3,500 participants across 11 countries.
"This study highlights the generalized applicability of the results in addressing cardiovascular health disparities," noted a Cleerly representative. The diverse trial population provides robust evidence for the technology's effectiveness across different demographics and healthcare systems.
AI Technology for Personalized Cardiac Assessment
Cleerly's FDA-cleared AI solutions enable comprehensive phenotyping of coronary artery disease through advanced noninvasive CT imaging. The technology analyzes coronary computed tomography angiography (CCTA) scans to guide personalized prognosis, diagnosis, and treatment planning.
The company's approach is built on extensive scientific validation, with their algorithms trained on millions of images from over 40,000 patients. Their COMPARE feature, which will be demonstrated at ACC.25, allows clinicians to track plaque progression over time, enabling more proactive management of cardiovascular disease.
Health Equity Focus
Beyond the clinical trial presentation, Cleerly will participate in several sessions focused on health equity and female representation in cardiovascular medicine. Dr. James Min, Cleerly's founder and CEO, will join the Health Equity Panel on March 30th from 2:30-3:30 PM, discussing "Championing Communities of Health: A Cross-Industry Panel Discussion on Community Education, Cardiovascular Disease Prevention, and Screening Programs."
The company will also participate in a Lounge & Learn Session titled "Increasing Female Physician Leadership in Clinical Trials" on March 30th from 1:00-1:30 PM, further emphasizing their commitment to addressing gender disparities in cardiac care and research.
Additional Research Presentations
Cleerly will present six additional abstracts throughout the conference, showcasing various aspects of their AI technology and its applications in cardiovascular health assessment. These presentations will cover advancements in heart health technology and research methodologies.
Conference attendees can visit Cleerly at booth #16033 to see demonstrations of their technology and attend the "Meet Cleerly Leadership" event on Sunday, March 30th from 12:30 to 1:30 PM for discussions with company leadership.
Transforming the Standard of Care
Cleerly's mission centers on eliminating heart attacks by creating a new standard of care for heart disease. Their AI-driven approach aims to enhance health literacy for all stakeholders in the coronary care pathway, from patients to providers.
The presentation of the CONFIRM2 registry results at ACC.25 represents a significant step toward more personalized and equitable cardiovascular care, particularly for women who have historically been underrepresented in cardiac research and often receive delayed or inadequate treatment for coronary artery disease.
